Abstract
Introduction
TP53 is well known as the most commonly mutated gene in human cancer [1] . The gene product is a 53-kD phosphoprotein of 393 amino acids, forming five highly conserved regions and four functional domains [2] . In response to a stress signal, the p53 protein is activated by post-translational modifications. These modifications stabilize p53, intracellular levels rise and p53 is activated as a transcription factor to direct stress-specific transcriptional response programs, leading to cell cycle arrest, cell senescence or apoptosis. p53 acts as a central node in the cellular network of stress responses, with multiple divergent inputs that regulate p53 activity and multiple outputs from activated p53 [3, 4] . [5] . The ability of another member of the p53 family, p73, to interact with and partially compensate for loss of p53 activity is another emerging factor of importance for p53 function and has been suggested to be important for tumour response to some genotoxic therapies [6] .
The mutations of TP53 gene seen in human cancers result in an inactive protein which is unable to initiate appropriate stress responses, leading to both enhanced tumourigenic potential and impaired responses to therapeutic agents. In addition to mutations in the TP53 gene coding sequence, p53 activity may also be decreased by alterations of genes that act as regulators of p53 activity. MDM2 is one major regulator, which degrades p53 and the importance of this regulatory pathway is underscored by the observation of overexpression of MDM2 by gene amplification in a significant proportion of human cancers
It is therefore conceivable that the existence of natural variants of p53 and other proteins that influence p53 activity could be linked with the development of tumours in the human population and could represent predictive biomarkers for preventive and early intervention strategies. A total of 38 polymorphisms in the TP53 gene are referred to in SNP500 Cancer Database [7] (http://snp500cancer.nci.nih.gov/home_1.cfm). Most of these natural variants are localized in introns, although polymorphisms also exist in exons of TP53. Some of these TP53 polymorphisms have been analysed in large populations ( Fig. 1 ) whereas other polymorphisms have been described rarely and their significance remains to be determined. In addition, polymorphisms in genes that regulate p53 or are regulated by p53 have been described. Here, we review the evidence that polymorphisms in the p53 pathway are important determinants of cancer predisposition in the human population.
SNPs in TP53 exons altering amino-acid sequence
The substitution of proline (codon CCG) to serine (codon TCG) at residue 47 (P47S) , and the substitution of arginine (codon CGC) to proline (codon CCC) at residue 72 (R72P) , both localized in exon 4, are among the most intensively studied polymorphisms found in the coding regions of TP53 which alter the amino-acid sequence. [8] . In vitro studies have shown that the S47 variant is not as good a substrate for the nearby phosphorylation at S46 by p38 mitogen-activated protein kinase (MAPK) and has impaired pro-apoptotic ability due to a decreased transcriptional activation of p53AIP1 and p53-upregulated modulator of apoptosis (PUMA) [9] . Although these data suggest that individuals with this polymorphism will be at higher risk for tumour development and have a relatively impaired response to therapy, there are as yet no firm data in large population studies that confirm these suggestions, partly due to the rarity of the polymorphism.
Felley-Bosco et al. first identified single nucleotide polymorphism (SNP) P47S and found that polymorphic variant S47 is very rare in African Americans and undetectable in Caucasians
The codon R72P SNP results in a structural change of the protein [10, 11] of p53 that binds to this proline-rich domain of p53, interacts more strongly with the P72 variant leading to inhibition of apoptosis [14] . In contrast, Dumont et al. showed that stronger interaction of the R72 variant with the nuclear-export protein CRM1 leads to enhanced nuclear export and accumulation in mitochondria resulting in release of cytochrome c into the cytosol [15] . Additionally they suggested that the R72 form had a higher affinity for MDM2 than the P72 form resulting in enhanced ubiquitination by this ubiquitin ligase [15] . The ability of mutant p53 proteins to bind p73 and inhibit its apoptotic activity in tumours is another important factor (Table 1) [16, 17] . However, the in vitro response of cells exposed to anticancer agents is strongly influenced by this SNP in wild-type p53 as well [20] . To [22] . Further small-scale population analysis of women in Italy revealed that this increased susceptibility to degradation by E6 is associated with higher incidence of cervical cancer in HPV-infected women who were homozygous for the R72 variant [22] . Although there have been several reports worldwide, the question whether [23] or not [24] [25] [26] [ 15, 20] Degradation Wt R72 allele has greater capacity to interact with MDM2. [15] R72 was found more efficiently targeted for degradation by the E6 protein of HPV16. [22] Gain of function mut The R72 allele is preferentially mutated and these mutants confer stronger affinity for interaction with p73 followed by its inactivation.
[ [16] [17] [18] Response to chemotherapy Wt R72 allele cases have higher response rates and longer survival than those with P72. [20] P72 variant is more frequent and tumours are less sensitive to apoptosis-inducing treatment. [32] [34] . This is consistent with the preferential mutation of the p53 R72 allele found in squamous tumours [17] . [37] . Analyses by other groups have revealed an 11 year earlier age of onset in individuals with at least one P72 allele for oral cancer, and a 6-year earlier age of onset for squamous carcinoma of the head and neck [38] . These trends may be explained by the increased apoptotic potential of the R72 variant, as well as the findings that individuals with the R/R genotype have higher response rates and better survival after receiving chemo-and radiation therapy for advanced head and neck cancer [20] and for cancers of the breast and lung [30, 39, 40] [41] . [44, 45] , G to A transversion in intron 6 at nucleotide 13494 (G13494A) often reported as MspI [46] or BstNI/NciI polymorphisms [47] and a G to C transversion in intron 6 at nucleotide 13964 (G13964C) [44, 45] [49] , other studies found no such association [50] [51] [52] . [59, 60] . Further it was also determined that the p53 haplotypes were associated with risk for lung [60] [61] [62] , colorectal [63] , breast [33, 64] and other cancers [65, 66] . [67] , and both TP53 polymorphisms P72 and 16bp insertion are associated with higher incidence of lymph node metastases [49] . Further studies are needed to determine the mechanism by which exon 4 and introns 3 and 6 variants modify cancer risk.
Polymorphism in TP53 introns

Generally these data highlight the value of examining multiple polymorphisms in TP53 gene, which could be critical for risk of developing tumours, risk of progression, and prognostic effects. For example, occurrence of the multivariant alleles from TP53 exon 4 and intron 3 results in a significantly poorer prognosis in non-small cell lung cancer
Silent mutations and SNPs in TP53
Silent mutations are a potentially interesting group of TP53 gene polymorphisms. These SNPs change one codon for another synonymous one, and for this reason do not affect the structure of the gene product. The predominant view is that these synonymous mutations are effectively neutral and consequently they play no role in carcinogenesis. Nevertheless it has been proposed that silent mutations are not necessarily neutral [68, 69] [70, 71] . Another possible explanation is that alterations in mRNA splicing are an important cause of genetic diseases, and in particular they are relatively common in cancer [72] . Point [75] [76] [77] [79] . It is also the case of the polymorphism in codon 36 (CCG→CCA) in TP53 gene described by Felix et al. [80] . This polymorphism has been described in several publications; however, no association with a specific phenotype has been described so far. (Fig. 1 [88] . To test the hypothesis that the TP73 G4C14 to A4T14 polymorphism is associated with risk of cancers, several hospital based case-control studies have been done (Table 3) . These studies provide evidence that TP73 AT variant is significantly associated with an increased risk of squamous cell carcinoma of the head and neck (SCCHN), endometrial cancer and lung cancer [89] [90] [91] . On the other hand, some studies suggest that the AT variants possess a protective role against cancer development [92, 93] and a study of 526 breast cancer patients showed an association of AT variant with longterm survival [94] . Although inconsistent, these results raise the possibility that analysis of TP73 polymorphism may provide useful prognostic information for cancer patients. Nevertheless, additional independent studies are needed to confirm these findings. [95] . An expressionbased analysis of primary tumour material suggests that the 73 bp deletion in the first intron of the TP73 gene and different expression levels of ZEB1 and p300 may act in concert to affect the ratio of TAp73/⌬TAp73 forms, favouring p73 oncogenic variants (Fig. 2A) . In addition, up-regulation of p73 oncogenic isoforms predicts a poor prognosis based on its relationship with advanced tumour stage [87, 96] . However, it is still unclear whether the presence of the deletion increases tumour susceptibility, or whether the effects are seen only on prognosis and further large-scale studies are required. In addition, the influence of this polymorphism on p53 responses are unclear, but might for example be expected to diminish even further the relatively decreased pro-apoptotic ability of the P72 allele of TP53, due to an increase in ⌬Np73/p73 ratios, enhancing tumour susceptibility. As noted above, in tumours with mutant p53, an opposite effect on prognosis may be seen. To date no studies have investigated these possibilities.
. Silent mutations may affect the function of the gene in many different ways. The most classical view is related to the different usage of synonymous codons resulting in different translational rate
. It was shown that silent mutations, especially those mutations that were always found as singlet and never as a doublet or as a multiplet, tend to be preferentially located inside candidate exonic splicing enhancers motifs [68]. Moreover in TP53, all exonic CpG sequences are methylated. This epigenetic modification is correlated with frequent G:C→A:T transitions [78]. Interestingly, it was found that silent mutations are non-random, mostly involving G:C→A:T transitions (62%) as well
Polymorphisms in other members of the p53 family
). Whereas the promoter 3 variant did not have a significant biological effect, there are several studies indicating that the two SNPs localized at position 4 (G to A) and 14 (C to T) in the 5Ј-untranslated region of exon 2 of TP73 gene may be associated with an increased risk of certain types of cancer. These two polymorphisms are in complete linkage disequilibrium with one another and form a polymorphism referred to as the AT and GC alleles. This polymorphism lies upstream of the initiating codon AUG of exon 2, a region which may theoretically form a stem-loop structure that could potentially affect gene expression through alteration of the efficiency of translation initiation
A novel regulatory region of p73 expression has been identified in a 1 kb stretch of intron 1 upstream of the initiating ATG codon in exon 2. This region contains six sites for binding of the transcriptional repressor ZEB1 (␦EF1), whose inhibition leads to increased expression of p73. Interestingly the 73 bp deletion in intron 1 is localized just between Ϫ489 and Ϫ417 of this negatively regulated fragment and was observed to be statistically more frequent in individuals with a diagnosis of breast or colorectal carcinomas compared to healthy controls
Polymorphisms in p53 target genes
There is clear evidence that increases in the levels of the MDM2 protein attenuate p53 function, leading to cancer formation [97] . A SNP at nucleotide 309 which lies in intron 1 and is within the MDM2 promoter was found to be associated with the attenuation of the p53 pathway and with the acceleration of tumour formation [ 95] in humans [98] . The SNP changes a T to a G (the G allele is designated SNP309, and occurs at high frequency) creating a higher affinity Sp1 binding site, which is suggested to increase MDM2 mRNA levels (Fig. 2B) . In most publications, the association of MDM2 SNP309 with cancer was connected with the Li-Fraumeni syndrome or with p53 mutational status [99] [100] [101] . Studies associating SNP309 with sporadic cancer risk have provided conflicting results: either no increased risk of breast and ovarian cancer was observed [102, 103] or accelerated tumour and hormone-dependent manner formation was seen in a genderspecific manner [104, 105] . [106] , nor could we find an increase in MDM2 protein levels in primary tumour material [107] . These data are similar to those seen in mantle cell lymphomas [108] . [121] [122] [123] .
Polymorphisms in p53 response elements
The main functions of p53 as a tumour suppressor lie in the ability to transcriptionally regulate genes through binding to the p53 response element. A computational search of SNPs in putative p53 REs in promoter regions identified hundreds of SNPs that alter the sequence of p53 REs [124] . Functional analysis of a small subset of these, including genes with known roles in tumourigenesis showed that the variant SNPs render the REs less able to mediate p53-induced transcription. Thus, there are numerous genes that are involved in mediating p53 pathway responses that are functionally polymorphic for p53 activation [125] . For example, a C-to-T polymorphism in the VEGF receptor/Flt-1 promoter, creates a p53 RE in the less common Flt-1T variant (6% of the population) and only this variant induces expression after p53 activation (Fig. 2C) [126] . Further studies have also demonstrated the critical role for oestrogens identifying the second regulatory sequence within the Flt-1 promoter harbouring a partial response element for oestrogen receptors upstream of the p53 binding site [127] . Their finding suggested that this polymorphism could influence tumour formation/progression in a hormone-sensitive manner. There are no studies to date that have investigated the epidemiology of these SNPs in human cancers, but it seems likely that their influence on the ability to respond to wild-type p53 will affect cancer risk and response to treatment [125] . 
Concluding remarks
